Valacyclovir: Approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 11, 2010, Pages 1901-1913

  Vigil, Karen J ^a   Chemaly, Roy F ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antiviral; Herpes simplex; Herpes zoster; Valacyclovir

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR; ANTIVIRUS AGENT; VALINE;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GENITAL HERPES; HEADACHE; HERPES LABIALIS; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; REVIEW; SINGLE DRUG DOSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS TRANSMISSION; ADULT; ANALOGS AND DERIVATIVES; DRUG APPROVAL; HERPESVIRIDAE INFECTIONS; IMMUNOCOMPROMISED PATIENT; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; DRUG APPROVAL; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VALINE;

EID: 77954781227     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.494179     Document Type: Review

References (78)

1. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections, an evidence-based review. Arch Intern Med 2008;168:1137-1144
2. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44:S1-26
3. De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147:1-11
4. Fletcher CV, Englund JA, Edelman CK, et al. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 1991;35:938-943
5. Lowance D, Neumayer HH, Legendre CM, et al.; International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-1470 (Pubitemid 29220545)
6. Winston DJ, Yeager AM, Chandrasekar PH, et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003;36:749-758
7. Talarico CL, Burnette TC, Miller WH, et al. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999;43:1941-1946
8. Brigden D, Whiteman P. The mechanism of action, pharmacokinetics and toxicity of acyclovir - a review. J Infect 1983;6:3-9
9. Wang L, Schultz M, Weller S, et al. Pharmacokinetics and safety of valacyclovir, an acyclovir prodrug, in geriatric volunteers with and without concomitant diuretic therapy (Abstract P16). J Am Geriatr Soc 1993;41(Suppl 10):SA23
10. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valacyclovir, after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605
11. Perry CM, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infections. Drugs 1996;52:754-772
12. Hoshino Y, Katano H, Zou P, et al. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol 2009;83:11857-11861
13. Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992;36:1589-1595
14. Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293-296
15. Safrin A, Crumpacker C, Chatis P, et al.; AIDS Clinical Trials Group. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-555
16. Schillinger JA, McKinney CM, Garg R, et al. Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004. Sex Transm Dis 2008;35:599-606
17. Spruance SL, Jones TM, Blatter MM, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003;47:1072-1080
18. Fife KH, Barbarash RA, Rudolph T, et al.; Valaciclovir International Herpes Simplex Virus Study Group. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481-486
19. Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996;156:1729-1735
20. Bodsworth NJ, Crooks RJ, Borelli S, et al.; International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997;73:110-116
21. Abudalu M, Tyring S, Koltun W, et al. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008;47:651-658
22. Reitano M, Tyring S, Lang W, et al.; International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603-610
23. Patel R, Bodsworth NJ, Woolley P, et al.; International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997;73:105-109
24. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33:529-533
25. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20
26. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-1609
27. Hanania MM, Brietstein D. Postherpetic neuralgia: a review. Cancer Invest 1997;15:165-176
28. Schmader K. Management of herpes zoster in elderly patients. Infect Dis Clin Pract 1995;4:293-299
29. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-1553
30. Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis 2003;71:239-242
31. Rooney JF, Starus SE, Mannix ML, et al. Oral acyclovir to supress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 1993;118:268-272
32. Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing regimens. Dermatol Surg 2000;26:50-54
33. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ 1997;314:1800-1803
34. Colin J, Prisant O, Cochener B, et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000;107:1507-1511
35. Aizman A, Johnson MW, Elner SG. Treatment of acute retinal necrosis syndrome with oral antiviral medications. Ophthalmology 2007;114:307-312
36. Hato N, Yamada H, Kohno H, et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo-controlled study. Otol Neurotol 2007;28:408-413
37. Engstrom M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008;7:993-1000
38. Lerner AM, Beqaj SH, Deeter RG, et al. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Drugs Today (Barc) 2002;38:549-561
39. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo 2007;21:707-713
40. Balfour HHJ, Hokanson KM, Schacherer RM, et al. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol 2007;39:16-21
41. Dickerson FB, Boronow JJ, Stallings CR, et al. Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry 2003;160:2234-2236
42. Dickerson FB, Stallings CR, Boronow JJ, et al. Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus. Schizophr Res 2009;107:147-149
43. Saral R, Burns WH, Prentice HG. Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients. Clin Haematol 1984;13:645-660
44. Bustamante CI, Wade JC. Herpes simplex virus infection in the immunocompromised cancer patient. J Clin Oncol 1991;9:1903-1915
45. Liesveld JL, Abboud CN, Ifthikharuddin JJ, et al. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biol Blood Marrow Transplant 2002;8:662-665
46. Warkentin DI, Epstein JB, Campbell LM, et al. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother 2002;36:1525-1531
47. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-1238
48. Glenny AM, Fernandez Mauleffinch LM, et al. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 2009;21:CD006706
49. Kusne S, Schwartz M, Breinig MK, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991;163:1001-1007
50. Pettersson E, Hovi T, Ahonen J, et al. Prophylactic oral acyclovir after renal transplantation. Transplantation 1985;39:279-281
51. Seale L, Jones CJ, Kathpalia S, et al. Prevention of herpes virus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985;254:3435-3438
52. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009;43:757-770
53. Drugs for non-HIV viral infections. Treat Guidel Med Lett 2005;3:23-32
54. Boeckh M. Prevention of VZV using antiviral agents. Herpes 2006;13:60-65
55. Egan JJ, Carroll KB, Yonan N, et al. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant 2002;21:460-466
56. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS ONE 2009;4:e5512
57. Vusirikala M, Wolff SN, Stein RS, et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant 2001;28:265-270
58. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:3050-3056
59. Sheffield JS, Hill JB, Hollier LM, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol 2006;108:141-147
60. Money D, Steben M, Society of Obstetric and Gynaecologists of Canada. SOGC clinical practice guidelines: guidelines for the management of herpes simplex virus in pregnancy. Int J Gynaecol Obstet 2009;104:167-171
61. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002;186:S40-6
62. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998;177:48-56
63. Sheffield JS, Fish DN, Hollier LM, et al. Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol 2002;186:100-102
64. Zeng L, Nath CE, Blair EYL, et al. Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrob Agents Chemother 2009;53:2918-2927
65. Spruance SL, Stewart JC, Rowe NH, et al. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161:185-190
66. Spruance SL, Bodsworth N, Resnick H, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006;55:47-53
67. Bryson YJ, Dillon M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med 1983;308:916-921
68. Loveless M, Sacks SL, Harris JRW. Famciclovir in the management of first episode genital herpes. Infect Dis Clin Pract 1997;6:S12-16
69. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984;251:2103-2107
70. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996;276:44-49
71. Corey L, Bodsworth N, Mindel A, et al. An update on short-course episodic and prevention therapies for herpes genitalis. Herpes 2007;14:5A-11A (Pubitemid 47233676)
72. Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8-13
73. Lebreun-Vignes B, Bouzamondo A, Dupuy A, et al. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol 2007;57:238-246
74. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997;157:343-349
75. Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988;85:79-83
76. Tying S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995;123:89-96
77. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004;29:248-253
78. Baker DA, Blythe JG, Miller JM. Once daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Obst et Gynecol 1999;94:103-106